a couple of big announcements out so far this morning!
AHZ has demonstrated outstanding performance of CardioCel® in the reconstruction of heart valves compared to the control, and notably that valves in the CardioCel® repaired group demonstrated significantly reduced calcification versus the control as well as minimal thickening of the tissue.
In what will be even bigger news, SPL has gone into a trading halt before the release of its Phase III trial results before the start of trade tomorrow. Definitely one to watch!
